# Large-scale human myeloma cell line small molecule compound screen dataset

## TL;DR

This study screens 1,912 small molecules against 47 human myeloma cell lines to identify potential new treatments and biomarkers for multiple myeloma.

## Contribution

The novel contribution is a large-scale, publicly available dataset of small molecule compound screening results on human myeloma cell lines.

## Key findings

- A dataset of 1,912 small molecule compounds tested at 11 doses across 47 human myeloma cell lines is provided.
- The dataset includes raw and processed data along with metadata and high-level characterizations of drug responses.
- The dataset and analysis workflows are publicly accessible for further research and validation.

## Abstract

Multiple myeloma, a hematopoietic malignancy of terminally differentiated B cells, is the second most common hematological malignancy after leukemia. While patients have benefited from numerous advances in treatment in recent years resulting in significant increases to average survival time following diagnosis, myeloma remains incurable and relapse is common. To help identify novel therapeutic agents with efficacy against the disease and to search for biomarkers associated with differential response to treatment, a large-scale pharmacological screen was performed with 1,912 small molecule compounds tested at 11 doses for 47 human myeloma cell lines (HMCL). Raw and processed versions of the drug screen dataset are provided, as well as supportive information including drug and cell line metadata and high-level characterization of the most salient features of each. The dataset is publicly available at Zenodo and the workflow code used for data processing and generation of supporting figures and tables are available on GitHub.